Stock Groups

Biomarin Pharma Earnings, Revenue Beat in Q4 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Biomarin Pharma earnings beats revenue in quarter four

Biomarin Pharma (NASDAQ) reported Wednesday that the fourth quarter beat analyst forecasts, and that revenue exceeded expectations.

Biomarin Pharma posted earnings per share in the range of $-0.32 to $449.81M on revenues. Investing.com polled analysts and predicted EPS at $-0.36 for revenue $442.09M.

Biomarin Pharma shares rose 2% over the first of the year but are still below 12.40% of its 52-week peak of $94.20, which was set on February 10. Their performance is better than the, which is down 17.22% over the beginning of this year.

Biomarin Pharma is following other notable earnings in the Healthcare sector this month

Biomarin Pharma’s report follows an earnings beat by J&J on January 25, who reported EPS of $2.13 on revenue of $24.8B, compared to forecasts EPS of $2.12 on revenue of $25.28B.

Roche Holding ADR met expectations with fourth quarter earnings per share of $1.29 on $17.54B in revenue, as compared to $1.29 forecasted on $17.1B revenue.

You can keep up-to date on the latest earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information, including buy/sell signal data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]